After pushing the launch of its new cellulite treatment, Qwo, to this spring due to the pandemic, Malvern-based Endo International has been building momentum for what it sees as its potential blockbuster product, writes John George for the Philadelphia Business Journal.
This first injectable treatment for cellulite was approved by the FDA in July.
The company is targeting nearly 8.5 million women in the country as potential customers. According to Rob Catlin, vice president and general manager of Endo Aesthetics, Endo’s new division, that number represents women who are bothered by their cellulite enough to see a doctor about it and have the disposable income to purchase a treatment.
“It is not lost on us, as an organization, the importance of this launch,” said Patrick Barry, executive vice president and president of global commercial operations at Endo. “We see the cellulite market as a large market with a large unmet need. We are thrilled to be launching the first injectable treatment for cellulite.”
For the launch, Endo has hired around 90 sales professionals and has already introduced an unbranded education campaign titled “Really, cellulite.”
Read more about Endo in the Philadelphia Business Journal here.